Premium
Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem‐cell transplant recipients. The trough level is not enough
Author(s) -
Schrauder A.,
Saleh S.,
Sykora K. W.,
Hoy H.,
Welte K.,
Boos J.,
Hempel G.,
Grigull L.
Publication year - 2009
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/j.1399-3046.2008.00968.x
Subject(s) - medicine , trough level , pharmacokinetics , therapeutic drug monitoring , population , urology , ciclosporin , trough concentration , pharmacology , gastroenterology , transplantation , surgery , anesthesia , environmental health , tacrolimus
In order to monitor CsA serum levels after SCT, trough levels (C0) are widely used. The aim of this study was to estimate the population and individual PK parameters for patients receiving intravenous CsA after SCT. In 27 pediatric patients after SCT receiving CsA (3 mg/kg/day) every 12 h, a total of 289 CsA concentrations was obtained. To describe the PK parameters of CsA, a two‐compartment model with first order elimination was used. Covariate analysis identified body weight, age, and the co‐administration with itraconazole and tobramycine as factors influencing the Cl. The statistical comparison of AUC, trough level, and C2 indicates a correlation between AUC and C2, but no correlation between the AUC and C0, r = 0.24 (p = 0.146) vs. r = 0.526 (p = 0.000692), respectively. Our results underscore the fact that CsA trough levels do not reflect the drug exposure in patients receiving intravenous CsA after SCT. By contrast, CsA blood levels measured 2–6 h after CsA infusion showed a better correlation with the AUC. Our data provide new information to optimize the balancing act between GvHD‐prophylaxis, graft vs. leukemia effect, and CsA side‐effects after SCT.